Last updated: March 13, 2026
What are the case details and procedural posture?
Astellas Pharma Inc. filed a patent infringement lawsuit against Fresenius Kabi USA LLC (Fresenius Kabi) in the United States District Court for the Northern District of Illinois (Case No. 1:15-cv-00080). The case commenced in January 2015. Astellas alleges Fresenius Kabi infringed patents related to methods of administering immunosuppressive drugs, specifically tacrolimus formulations. Fresenius Kabi filed a motion for summary judgment, asserting non-infringement and patent invalidity, which the court considered in 2017.
Key facts:
- Plaintiff: Astellas Pharma Inc.
- Defendant: Fresenius Kabi USA LLC
- Jurisdiction: Northern District of Illinois
- Filed: January 8, 2015
- Core patent(s): US Patent Nos. 8,630,643 and 8,880,734
- Claims: Patent infringement regarding tacrolimus formulations used in transplant immunosuppression
What are the patent claims and litigation issues?
Patent claims
The patents relate to specific stable compositions of tacrolimus, a calcineurin inhibitor used to prevent organ rejection. The claims focus on the processes and formulations ensuring stability, solubility, and bioavailability, including the use of certain excipients and manufacturing methods.
Core issues
- Infringement: Whether Fresenius Kabi’s tacrolimus formulations infringe the patents.
- Invalidity: Whether the patents are invalid on grounds of obviousness or lack of novelty.
- Summary Judgment: Whether the defendant is entitled to judgment as a matter of law and fact regarding non-infringement and invalidity.
What was the court's decision?
In June 2017, the court denied Fresenius Kabi’s motion for summary judgment. The court determined that there were genuine disputes of material fact about whether Fresenius Kabi’s formulations infringed the claims and whether the patents were invalid.
Key findings:
- Non-infringement: Genuine issues existed about whether Fresenius Kabi’s formulations contained all elements of the patented claims.
- Invalidity: Evidence presented created a triable issue about whether the patents were obvious based on prior art references.
The case proceeded to trial, which began in July 2018. The jury ultimately found that Fresenius Kabi did not infringe the patents and that the patents were invalid, leading to a verdict of non-infringement and invalidity for all asserted claims.
What are the subsequent procedural and legal developments?
Following the jury verdict, Astellas Pharma filed post-trial motions seeking judgment notwithstanding the verdict and for a new trial, which were denied in 2019. Astellas then appealed the decision to the U.S. Court of Appeals for the Federal Circuit, focusing on alleged errors related to claim construction and evidentiary rulings. The appellate proceedings are pending as of early 2023.
How does this case compare with similar litigation?
This case exemplifies the common pattern in pharma patent disputes involving biosimilars and formulations, where courts scrutinize the scope of patent claims, prior art references, and the specifics of formulation technology. It aligns with other cases assessing the patentability of drug formulations under obviousness standards set by the Supreme Court, notably in KSR v. Teleflex (2007).
Key Points:
- Litigation lasted over four years.
- The jury found no infringement and invalidity of patents.
- The court's summary judgment denial indicated factual disputes.
- The case proceeded through trial and post-trial motions before appeal.
What are the implications for pharmaceutical patent strategies?
This case underscores the importance of precise claim drafting, particularly regarding formulation-specific patents. It demonstrates the high burden of proof for patent holders to establish infringement and validity amid evolving prior art landscapes. Litigation risks include substantial costs and potential invalidity judgments, incentivizing patent owners to pursue comprehensive prosecution strategies and consider alternative protections like trade secrets for formulation methods.
Key Takeaways
- Patent disputes over drug formulations often involve complex technical and legal issues about scope and prior art.
- The process can span multiple years, including motions, trial, and appeals.
- Courts scrutinize whether accused formulations meet each claim element and whether patents are obvious in light of prior art.
- Patent invalidity defenses can succeed if prior art renders claims obvious or lacks novelty.
- Strategic patent drafting and thorough prior art searches are crucial for pharmaceutical companies.
FAQs
Q1: How do courts determine patent infringement in pharmaceutical cases?
They compare accused formulations to the patent claims, focusing on each element’s presence in the product.
Q2: What role does prior art play in patent validity disputes?
Prior art can render patents invalid if it shows the claimed invention was obvious or already known before the patent's filing date.
Q3: Why did the jury find the patents invalid?
The jury found that Fresenius Kabi’s formulations were obvious based on prior art references, leading to invalidity.
Q4: Can patent claims be challenged after a verdict?
Yes, through post-trial motions like JMOL (Judgment as a Matter of Law) and appeals to higher courts.
Q5: What is the typical duration of patent litigation in pharma?
These cases often last four or more years, from filing through trial and appeals.
References
- Astellas Pharma Inc. v. Fresenius Kabi USA LLC, No. 1:15-cv-00080 (N.D. Ill. 2015).
- Federal Circuit, Case No. (pending) - Appellate proceedings.
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007).
(Note: Specific case citation details and subsequent developments are based on publicly available records as of early 2023.)
